Li+   Click here for help

GtoPdb Ligand ID: 5212

Synonyms: lithium ion
Approved drug
Li+ is an approved drug (FDA (1970))
Compound class: Inorganic
Comment: Lithium is a long-standing psychiatric medicine of unclear mechanism. A number of enzymes have been proposed as potential targets of lithium action, including inositol monophosphatase, a family of structurally related phosphomonoesterases, and the protein kinase glycogen synthase kinase-3 (see [4] and the DrugBank link). Administered as salt formulations such as the carbonate PubChem CID 11125
Click here for help
IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: lithium

1. Brown KM, Tracy DK. (2013)
Lithium: the pharmacodynamic actions of the amazing ion.
Ther Adv Psychopharmacol, 3 (3): 163-76. [PMID:24167688]
2. McAllister G, Whiting P, Hammond EA, Knowles MR, Atack JR, Bailey FJ, Maigetter R, Ragan CI. (1992)
cDNA cloning of human and rat brain myo-inositol monophosphatase. Expression and characterization of the human recombinant enzyme.
Biochem J, 284 ( Pt 3): 749-54. [PMID:1377913]
3. Oruch R, Elderbi MA, Khattab HA, Pryme IF, Lund A. (2014)
Lithium: a review of pharmacology, clinical uses, and toxicity.
Eur J Pharmacol, 740: 464-73. [PMID:24991789]
4. Phiel CJ, Klein PS. (2001)
Molecular targets of lithium action.
Annu Rev Pharmacol Toxicol, 41: 789-813. [PMID:11264477]
5. Ryves WJ, Dajani R, Pearl L, Harwood AJ. (2002)
Glycogen synthase kinase-3 inhibition by lithium and beryllium suggests the presence of two magnesium binding sites.
Biochem Biophys Res Commun, 290 (3): 967-72. [PMID:11798168]
6. Ryves WJ, Harwood AJ. (2001)
Lithium inhibits glycogen synthase kinase-3 by competition for magnesium.
Biochem Biophys Res Commun, 280 (3): 720-5. [PMID:11162580]